scholarly journals Coexistence of Malignant Struma Ovarii and Cervical Papillary Thyroid Carcinoma

2013 ◽  
Vol 98 (12) ◽  
pp. 4599-4605 ◽  
Author(s):  
Aaron Leong ◽  
Philip J. R. Roche ◽  
Miltiadis Paliouras ◽  
Louise Rochon ◽  
Mark Trifiro ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Gland ◽  
Thyroid Carcinoma ◽  
Braf V600e ◽  
Field Cancerization ◽  
Cytokeratin 19 ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Malignant Struma Ovarii

Context: Struma ovarii is an uncommon monodermal teratoma in which thyroid tissue is the predominant element. Malignant transformation of struma ovarii is an even rarer occurrence. Case Presentation: We describe a 42-year-old woman who underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a symptomatic left pelvic mass. Histology revealed malignant struma ovarii with classical papillary thyroid carcinoma expression. Ultrasonography of the cervical neck showed thyroid micronodules and a dominant 1-cm nodule in the left thyroid lobe. As the ovarian tumor was large, the patient underwent a total thyroidectomy with the intention of administering 131I therapy in an adjuvant setting. Histology of the cervical thyroid gland revealed bilateral multifocal papillary thyroid carcinoma with extrathyroidal extension and perithyroidal lymph node metastasis. Methods: Morphological (microscopy), immunohistochemical (Hector Battifora mesothelial cell 1, cytokeratin-19, galectin-3), and molecular (BRAF V600E, RAS, RET-PTC) characteristics and clonality analysis of the cervical thyroid and ovarian tumors were explored to distinguish them as separate malignancies. Results: The thyroid-type tumors from the cervical gland and ovary were discordant in terms of tissue histology and level of cytokeratin-19 expression. The clinical features and tumor profile results supported the independent existence of these two embryologically related, although topographically distinct, malignancies. Conclusion: Our findings provided support for synchronous, albeit distinct, primary tumors in the ovary and cervical thyroid. “Field cancerization” and early genomic instability may explain multifocality in all thyroid-type tissue. In this regard, patients with malignant struma ovarii should undergo imaging of their thyroid gland for coexisting disease and thyroidectomy recommended for suspected malignancy or in preparation for radioiodine therapy.

BRAF V600E associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma

Endocrine ◽  
2012 ◽  
Vol 44 (1) ◽  
pp. 165-171 ◽  
Author(s):  
Anna Guerra ◽  
Vincenzo Marotta ◽  
Maurilio Deandrea ◽  
Manuela Motta ◽  
Paolo Piero Limone ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf V600e ◽  
Cytokeratin 19 ◽  
Papillary Thyroid

scholarly journals SUN-LB81 Coexisting Malignant Struma Ovarii and Cervical Follicular Variant Papillary Thyroid Carcinoma

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Jubran Afzal Khan Rind ◽  
Zeb Ijaz Saeed
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Mature Teratoma ◽  
Clinical Endocrinology ◽  
Lymphatic Invasion ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Lower Quadrant ◽  
Malignant Struma Ovarii

Abstract A 44-year-old woman presented with left lower quadrant abdominal pain for 2 months. Further evaluation revealed a left adnexal mass and she underwent a TAH-BSO. A 12 cm mass arising from the left ovary was resected which on microscopy appeared to be papillary thyroid carcinoma follicular variant arising from a mature teratoma (struma ovarii). A thyroid ultrasound showed two subcentimeter right thyroid nodules without any concerning lymphadenopathy. A total thyroidectomy was then performed to allow her to receive adjuvant RAI. The cervical thyroid pathology showed a 0.6 cm follicular variant papillary thyroid carcinoma with negative margins without angioinvasion, lymphatic invasion or extrathyroidal extension. Thyroid hormone suppression with levothyroxine was started. Preoperatively, thyroglobulin was 1381 ng/ml (nl range 1.3-31.8 ng/ml). After TAH-BSO and thyroidectomy, thyroglobulin was undetectable and so was the anti-thyroglobulin antibody. With an undetectable thyroglobulin level, it was decided not to pursue adjuvant RAI and continue TSH suppression with levothyroxine. Simultaneous existence of malignant struma ovarii and cervical papillary thyroid cancer is rare and has a favorable prognosis compared to metastasis to the ovaries from primary cervical thyroid papillary carcinoma. Due to the rarity of this condition, management is not clear or well supported by evidence. Various approaches are suggested by different authors, including thyroidectomy after resection of malignant struma ovarii to facilitate adjuvant RAI, only performing surgical resection of the ovarian tumor in the absence of high risk features or performing thyroidectomy and RAI only in metastatic or recurrent disease. References:1.Aaron Leong, Philip J. R. Roche, Miltiadis Paliouras, Louise Rochon, Mark Trifiro, Michael Tamilia, Coexistence of Malignant Struma Ovarii and Cervical Papillary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 12, 1 December 2013, Pages 4599-46052.Synchronous malignant struma ovarii and papillary thyroid carcinoma Pablo Fernández Catalina,Antonia Rego Iraeta, Mónica Lorenzo Solar, Paula Sánchez Sobrino DOI: 10.1016/j.endoen.2016.08.006

Synchronous malignant struma ovarii and papillary thyroid carcinoma

2016 ◽  
Vol 63 (7) ◽  
pp. 366-367
Author(s):  
Pablo Fernández Catalina ◽  
Antonia Rego Iraeta ◽  
Mónica Lorenzo Solar ◽  
Paula Sánchez Sobrino
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Malignant Struma Ovarii

Malignant Struma Ovarii with Papillary Thyroid Carcinoma: Case Report

2020 ◽  
Vol 46 (2) ◽  
pp. e110
Author(s):  
Ana Paulina Melendez ◽  
Ana Gabriela Gongora ◽  
Anait Abad ◽  
Eugenio Abreu ◽  
Alejandro Martinez
Keyword(s):  
Case Report ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Malignant Struma Ovarii

scholarly journals A Hormonally Active Malignant Struma Ovarii

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Carolina Lara ◽  
Dalia Cuenca ◽  
Latife Salame ◽  
Rafael Padilla-Longoria ◽  
Moisés Mercado
Keyword(s):  
Thyroid Hormone ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Tissue ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Ovarian Teratoma ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Malignant Struma Ovarii

Struma ovarii is a rare monodermal variant of ovarian teratoma that contains at least 50% thyroid tissue. Less than 8% of struma ovarii cases present with clinical and biochemical evidence of thyrotoxicosis due to ectopic production of thyroid hormone and only 5% undergo malignant transformation into a papillary thyroid carcinoma. Only isolated cases of hormonally active papillary thyroid carcinoma developing within a struma ovarii have been reported in the literature. We report the case of a 36-year-old woman who presented with clinical signs and symptoms of hyperthyroidism as well as a left adnexal mass, which proved to be a thyroid hormone-producing, malignant struma ovarii.

scholarly journals The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Yuying Cui ◽  
Jinming Yao ◽  
Shengnan Wang ◽  
Junyu Zhao ◽  
Jianjun Dong ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Gene Mutations ◽  
Average Dose ◽  
Cancer Type ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Bilateral Oophorectomy ◽  
Malignant Struma Ovarii

The objective of this study is to summarize the clinical and pathologic characteristics of malignant struma ovarii to facilitate the early diagnosis and treatment of this disease. All 144 patients were females from 27 countries. The mean age of the patients at diagnosis was 42.6 years. Overall, 35.71% of the patients underwent unilateral oophorectomy, 58.57% of the patients underwent bilateral oophorectomy, 5.72% of the patients were not ovariectomized, and 38.57% of the patients received radioactive iodine treatment with an average dose of 158.22 mCI each time. “Impure” types accounted for 70.19% of the cases, while pure types accounted for 29.81% of the cases. Among these cases, papillary thyroid carcinoma accounted for 50.00%, follicular thyroid carcinoma accounted for 26.47%, follicular variant of papillary thyroid carcinoma accounted for 18.63%, papillary and follicular mixed thyroid carcinoma accounted for 2.94%, anaplastic carcinoma accounted for 0.98%, and medullary carcinoma accounted for 0.98%. In total, 21 patients (51.22%) had elevated CA125. More than half of the patients (51.94%) had metastasis outside the ovary. The most common metastatic site was the pelvic cavity. The misdiagnosis rate was 17.27%. Mortality was related to metastasis and the cancer type. Gene mutations were found in the NRAS, KRAS, BRAF, and KIT genes and were similar to those in thyroid carcinoma, but some patients (37.5%) did not exhibit any gene mutations. Regardless of the treatment received, the survival rate is high. Treatment could initially include ovariectomy; however, in cases with metastasis and iodine uptake of the metastatic tumor, thyroidectomy, radioactive iodine therapy, and thyroid hormone inhibiting therapy are indicated.

scholarly journals OP07.01: Malignant struma ovarii: a case of ovarian papillary thyroid carcinoma

2021 ◽  
Vol 58 (S1) ◽  
pp. 80-80
Author(s):  
A. Mundó Fornell ◽  
A. Delgado‐Morell ◽  
M. Pero ◽  
N. Rams
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Malignant Struma Ovarii
Sign in / Sign up

Export Citation Format

Share Document